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Abstract
Direct sequencing and reverse hybridization are currently the main methods for detecting drug-resistance mutations of hepatitis B virus
(HBV). However, these methods do not enable haplotype analysis so they cannot be used to determine whether the mutations are co-
located on the same viral genome. This limits the accurate identiﬁcation of viral mutants that are resistant to drugs with a high genetic
barrier. In our current study, ultra-deep pyrosequencing (UDPS) was used to detect HBV drug-resistance mutations in 25 entecavir-
treated and ﬁve treatment-naive patients. Of the 25 entecavir-treated patients, 18 had experienced virological breakthrough and two
exhibited reduced susceptibility to entecavir. The results obtained by UDPS were compared with those of direct sequencing, and the
haplotypes of the drug-resistant HBV mutants were analysed. The average number of reads per patient covering the region in which
drug-resistance mutations are located was 1735 (range 451–4526). UDPS detected additional drug-resistance mutations not detected by
direct sequencing in 19 patients (mutation frequency range 1.1–23.8%). Entecavir-resistance mutations were found to be co-located on
the same viral genome in all 20 patients displaying virological breakthrough or reduced susceptibility to entecavir. In conclusion, UDPS
was not only sensitive and accurate in identifying drug-resistance mutations of HBV but also enabled haplotype analysis of the mutants.
This method may offer signiﬁcant advantages in explaining and predicting the responses of patients with HBV to antiviral therapy.
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Abstract
Hepatitis B e-antigen (HBeAg)-negative chronic HBV infection is highly prevalent in several parts of the world, including India, with the
clinical spectrum ranging from inactive carrier (IC) state to chronic ‘e-negative’ hepatitis B (CHB) and culminating in advanced liver dis-
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ease such as cirrhosis (LC). The present study has for the ﬁrst time investigated the natural diversity of HBV belonging to genotype D
in treatment-naı¨ve Indian patients representing the above phases of HBeAg-negative infection to identify candidate mutations associated
with each disease state. Studies of full-length HBV/D sequences revealed that the progressive accumulation and persistence of mutations
in basal core promoter, negative regulatory element, Pre-core region, the B- and T-cell epitopes of X protein as well as deletions in the
PreS region contribute signiﬁcantly to disease progression from IC through CHB to LC. In addition, the development of CHB was asso-
ciated with a signiﬁcant increase in viral variants characterized by mutations in enhancer II, preS1 promoter, T-cell epitope of core and
B-cell epitope region of PreS1. While few of the mutations were previously reported in the context of HBV genotypes B and C, others
had not been documented before. Our results thus highlight a distinct pattern of mutation in HBV/D that may help in predicting clinical
outcomes of HBeAg-negative infection and have implications for better clinical management of the patients.
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Abstract
Cytomegalovirus (CMV) is the most prevalent infectious agent causing neurological dysfunction in the developing brain. This study ana-
lysed the different patterns of tissue damage, particularly in the brain, of fetuses with documented CMV infection. We studied 45
fetuses at 20–21 weeks of gestation with congenital CMV infection documented by invasive positive prenatal diagnosis. At the time of
amniocentesis, abnormal ultrasound ﬁndings had been recorded for 13 of the 45 fetuses (29%). Histological and immunohistochemical
characterization was performed on the placenta, brain, heart, lung, liver, kidney, and pancreas. The different degrees of brain damage
were correlated with tissue viral load, inﬂammatory response, placental functionality, and extramedullary haematopoiesis. Even though a
high CMV load was detected in all amniotic ﬂuids, brain infection occurred in only 62% of the fetuses and with different degrees of
severity. Tissues with a low viral load showed a globally weak inﬂammatory response, and fetuses had only mild brain damage, whereas
tissues with a high CMV load showed prominent inﬁltration of the activated cytotoxic CD8+ T-lymphocytes responsible for immune-
mediated damage. Furthermore, severe placental infection was associated with diffuse villitis and necrosis, consistent with functional
impairment and possible consequent hypoxic cerebral damage. Brain injury induced by CMV congenital infection may be the result of
uncontrolled viral replication, immune-mediated damage by cytotoxic CD8+ T-lymphocytes, and, in the presence of placental insufﬁ-
ciency, fetal hypoxia.
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